WGS

SEC source: 0001415889-24-025838 · form4-10312024_091002.xml · nonDerivative · entry 1

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-025837 · form4-10312024_091013.xml · derivative · entry 3

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,244

Underlying: Class A Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-025837 · form4-10312024_091013.xml · nonDerivative · entry 2

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,426

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-025837 · form4-10312024_091013.xml · nonDerivative · entry 1

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-025384 · form4-10172024_091046.xml · derivative · entry 2

RUCH JOSHUA · CIK 0000943431 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

SEC source: 0001415889-24-025384 · form4-10172024_091046.xml · nonDerivative · entry 1

RUCH JOSHUA · CIK 0000943431 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-025386 · form4-10172024_091007.xml · derivative · entry 2

Ryan Jason · CIK 0001585017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 130 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

SEC source: 0001415889-24-025386 · form4-10172024_091007.xml · nonDerivative · entry 1

Ryan Jason · CIK 0001585017 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-023619 · form4-09182024_080948.xml · derivative · entry 3

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,969

Underlying: Class A Common Stock · 7,197 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-023619 · form4-09182024_080948.xml · nonDerivative · entry 2

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,472

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-023619 · form4-09182024_080948.xml · nonDerivative · entry 1

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-023621 · form4-09182024_080934.xml · derivative · entry 3

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Class A Common Stock · 18,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-023621 · form4-09182024_080934.xml · nonDerivative · entry 2

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,706

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-023621 · form4-09182024_080934.xml · nonDerivative · entry 1

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,207

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-023264 · form4-09122024_120919.xml · derivative · entry 3

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,159

Underlying: Class A Common Stock · 2,462 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-023264 · form4-09122024_120919.xml · nonDerivative · entry 2

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,910

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001415889-24-023264 · form4-09122024_120919.xml · nonDerivative · entry 1

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-023262 · form4-09122024_120927.xml · derivative · entry 3

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,919

Underlying: Class A Common Stock · 6,546 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-023262 · form4-09122024_120927.xml · nonDerivative · entry 2

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,457

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction

SEC source: 0001415889-24-023262 · form4-09122024_120927.xml · nonDerivative · entry 1

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,096

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-022830 · form4-09042024_100920.xml · nonDerivative · entry 2

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,343

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.6053 to $31.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-022830 · form4-09042024_100920.xml · derivative · entry 3

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,739

Underlying: Class A Common Stock · 717 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-022830 · form4-09042024_100920.xml · nonDerivative · entry 1

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 3

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,646,972

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,696,972

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-098688 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,746,972

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-097135 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,786,796

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $35.9175, inclusive. The reporting person undertakes to provide to Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-097135 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,811,783

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.16 to $34.90, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-094224 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,871,570

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.20 to $32.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-094224 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,971,570

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.75, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000919574-24-004273 · ownership.xml · nonDerivative · entry 1

Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner

Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner

Casdin Eli · CIK 0001534264 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,507,164

F1 · kind: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 413,655 shares of Class A Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). No reporting person has any pecuniary interest in Casdin FO1.

F2 · ownership.direct: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

SEC source: 0000950170-24-089997 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,984,564

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.21, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-088679 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,073,403

F1 · balance_after: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from 33.56 to $34.16, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001415889-24-020433 · form4-07312024_080702.xml · derivative · entry 3

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,273

Underlying: Class A Common Stock · 753 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-020433 · form4-07312024_080702.xml · nonDerivative · entry 2

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,888

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-020433 · form4-07312024_080702.xml · nonDerivative · entry 1

Feeley Kevin · CIK 0001944119 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0001415889-24-020434 · form4-07312024_080747.xml · derivative · entry 3

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,118

Underlying: Class A Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F3 · derivative.expiration_date: 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001415889-24-020434 · form4-07312024_080747.xml · nonDerivative · entry 2

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,550

F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

SEC source: 0001415889-24-020434 · form4-07312024_080747.xml · nonDerivative · entry 1

Stueland Katherine · CIK 0001689575 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

SEC source: 0000950170-24-087048 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,123,403

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-087048 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,183,403

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.33, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 3

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,258,403

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $34.50, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,333,403

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $33.02, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-085751 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,383,403

SEC source: 0000950170-24-085008 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,408,403

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.18, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-082411 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,433,403

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.75, inclusive. The reporting person undertakes to provide to GeneDx Holdings Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 3

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,469,521

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.965, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 2

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,483,603

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $31.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0000950170-24-081596 · ownership.xml · nonDerivative · entry 1

OPKO HEALTH, INC. · CIK 0000944809 · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,508,603

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.4607 to $26.95, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001415889-24-018332 · form4-06272024_080659.xml · derivative · entry 1

RUCH JOSHUA · CIK 0000943431 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,924

Underlying: Class A Common Stock · 12,924 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.

F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.